Highlights China Medical System Holdings Limited

Equities

867 KYG211081248

Market Closed - Hong Kong S.E. Other stock markets 09:08:20 14/05/2024 BST			5-day change	1st Jan Change
7.46 ^HKD	-0.53%		+0.13%	-46.10%

04-23	China Medical System's Anti-Anaemia NDA Accepted in China	MT
04-23	China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Final dividend	05-12	FA
China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023	05-09	CI
China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China	04-23	CI
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	04-23	MT
China Medical System Registers New Vitiligo Drug in Macau	04-17	MT
China Medical System Holdings Limited commences an Equity Buyback for 245,198,851 shares, representing 10% of its issued share capital, under the authorization approved on April 28, 2023.	04-02	CI
Incyte, China Medical System Sign Collaboration, License Agreement	04-01	MT
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	04-01	CI
China Medical System Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024	03-27	CI
China Medical System's Atopic Dermatitis Cream Gets Regulatory Nod for Phase 3 Trial	03-20	MT
China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China	03-19	CI
China Medical System Obtains Nod For Trials of Two Drugs	02-08	MT
China Medical System Holdings Limited Announces CMS-D001 Tablets and CMS-D002 Capsules Self-Developed	02-07	CI
China Medical Gains License to Sell Kidney Disease Drug Across China	02-05	MT
China Medical System Holdings Limited Announces Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China	12-12	CI
China Medical System Holdings Limited Announces That on 4 December 2023, the New Drug Application for an Additional Indication of Methotrexate Injection Has Been Accepted by the National Medical Products Administration of China	12-04	CI
China Medical System Holdings Limited entered into the equity transfer agreement to acquire 15% stake in Hangzhou HealSun Biopharm Co., Ltd. from Lepu Biopharma Co., Ltd. for approximately CNY 130 million.	28/09/23	CI
Ex-dividend day for interim dividend	10/09/23	FA
China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 20, 2023	28/08/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights China Medical System Holdings Limited

Equities

867

KYG211081248

Highlights

Filters